⌕
Mirum Pharmaceuticals · MIRM · Nasdaq
Tenet 43 · Weak
Compare
$91.58−2.56%At closeTenet 43 · Weak
$91.58−2.41 (−2.56%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Mirum Pharmaceuticals (MIRM) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

● Business WireNov 12, 2026 · 16:01 ETCOMPANY'S OWN WORDS
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).…

● Zacks Investment ResearchNov 11, 2026 · 13:20 ET
MIRM's Brelovitug Scores Second Phase III Win, Nears BLA Filing in HDV

Mirum's brelovitug marks a second phase III win in chronic HDV, bringing the company closer to a planned 2027 BLA filing with the FDA.…

● ReutersNov 10, 2026 · 08:14 ET
Mirum's liver infection drug lowers virus levels in second late-stage study

Mirum's liver infection drug lowers virus levels in second late-stage study…

● Business WireNov 10, 2026 · 07:30 ETCOMPANY'S OWN WORDS
Mirum Pharmaceuticals Announces Primary Endpoint Met in AZURE-4 Phase 3 Study and Highlights Long-Term Brelovitug Data Presented at AASLD

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Announces Primary Endpoint Met in AZURE-4 Phase 3 Study and Highlights Long-Term Brelovitug Data Presented at AASLD.…

● Defense WorldNov 7, 2026 · 05:36 ET
Insider Selling: Mirum Pharmaceuticals (NASDAQ:MIRM) CEO Sells $1,800,000.00 in Stock

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM - Get Free Report) CEO Christopher Peetz sold 20,000 shares of the company's stock in a transaction on Wednesday, November 4th. The shares were sold at an average price of $90.00…

● Business WireNov 5, 2026 · 08:30 ET
GeneDx and Mirum Pharmaceuticals Launch Sponsored Testing Programs to Help Patients Find Answers Through Comprehensive Genetic Testing

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx and Mirum Pharmaceuticals Launch Sponsored Testing Programs to Help Patients Find Answers Through Comprehensive Genetic Testing.…

● Seeking AlphaNov 3, 2026 · 23:55 ET
Mirum Pharmaceuticals, Inc. (MIRM) Q3 2026 Earnings Call Transcript

Mirum Pharmaceuticals, Inc. ( MIRM ) Q3 2026 Earnings Call November 3, 2026 4:30 PM EST Company Participants Andrew McKibben - Senior Vice President, Strategic Finance & Investor Relations Christopher Peetz - CEO & Direc…

● MarketBeatNov 3, 2026 · 21:15 ET
Mirum Pharmaceuticals Q3 Earnings Call Highlights

Mirum Pharmaceuticals NASDAQ: MIRM reported third-quarter net product sales of $186 million and raised its full-year 2026 net product sales guidance to $715 million to $720 million, citing continued growth of LIVMARLI an…

● Zacks Investment ResearchNov 3, 2026 · 18:31 ET
Here's What Key Metrics Tell Us About Mirum Pharmaceuticals (MIRM) Q3 Earnings

While the top- and bottom-line numbers for Mirum Pharmaceuticals (MIRM) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to …

● Zacks Investment ResearchNov 3, 2026 · 18:15 ET
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q3 Loss, Tops Revenue Estimates

Mirum Pharmaceuticals, Inc. (MIRM) came out with a quarterly loss of $0.87 per share versus the Zacks Consensus Estimate of a loss of $0.53. This compares to earnings of $0.05 per share a year ago.…

● Business WireNov 3, 2026 · 16:01 ETCOMPANY'S OWN WORDS
Mirum Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update.…

● Business WireNov 2, 2026 · 08:02 ETCOMPANY'S OWN WORDS
Mirum Pharmaceuticals Showcases Momentum Across Rare Liver Disease Portfolio with New Data at AASLD's The Liver Meeting® 2026

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Showcases Momentum Across Rare Liver Disease Portfolio with New Data at AASLD's The Liver Meeting® 2026.…

● Zacks Investment ResearchOct 27, 2026 · 11:06 ET
Mirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Mirum Pharmaceuticals (MIRM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.…

● Business WireOct 26, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Mirum Pharmaceuticals Announces Positive Results from Cohort 2 of the Pivotal PROGRESS Study of ATEBRIOZ™ (zilurgisertib) in Pediatric Patients Aged 6 to

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Announces Positive Results from Cohort 2 of the Pivotal PROGRESS Study of ATEBRIOZ™ (zilurgisertib) in Patients Aged 6 to…

● Defense WorldOct 21, 2026 · 04:15 ET
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Stock Rated “Moderate Buy” by Wall Street Brokerages

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the fifteen ratings firms that are presently covering the company, MarketBeat reports. One a…

● Defense WorldOct 16, 2026 · 02:59 ET
Head-To-Head Survey: Kiniksa Pharmaceuticals International (NASDAQ:KNSA) versus Mirum Pharmaceuticals (NASDAQ:MIRM)

Mirum Pharmaceuticals (NASDAQ: MIRM - Get Free Report) and Kiniksa Pharmaceuticals International (NASDAQ: KNSA - Get Free Report) are both mid-cap healthcare companies, but which is the superior stock? We will compare th…

● Business WireOct 15, 2026 · 16:01 ETCOMPANY'S OWN WORDS
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).…

● Zacks Investment ResearchOct 13, 2026 · 11:45 ET
Mirum's Livmarli Meets Phase III Goal in Ultra-Rare Liver Diseases

MIRM's Livmarli meets the phase III EXPAND study goal, improving cholestatic pruritus and reducing serum bile acids, with an FDA filing planned for 2027.…

● Seeking AlphaOct 12, 2026 · 12:42 ET
Mirum Pharmaceuticals, Inc. (MIRM) Discusses Phase 3 EXPAND Study Results for Maralixibat in Cholestatic Pruritus Including Biliary Atresia Transcript

Mirum Pharmaceuticals, Inc. (MIRM) Discusses Phase 3 EXPAND Study Results for Maralixibat in Cholestatic Pruritus Including Biliary Atresia Transcript…

● Defense WorldOct 12, 2026 · 11:03 ET
Mirum Pharmaceuticals’ LIVMARLI Study Hits Key Endpoints in Rare Liver Diseases

Mirum Pharmaceuticals (NASDAQ: MIRM) said its Phase III EXPAND study of LIVMARLI, or maralixibat, met its primary endpoint and all prespecified secondary endpoints in pediatric patients with cholestatic pruritus associat…

● Business WireOct 12, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases.…

● Business WireOct 11, 2026 · 17:00 ETCOMPANY'S OWN WORDS
Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum to Host Call to Share Topline Results from the Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases.…

● Business WireSep 28, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus.…

No upcoming events in the feeds.

Article counts from the last market-wide feed page, across every symbol we track and not just MIRM · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.